Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Lauren Gelman: What is CreakyJoints?
April 16th 2021As a part of our partnership with CreakyJoints, Rheumatology Network sat down with Lauren Gelman, Director of Editorial Services, for the Global Healthy Living Foundation. CreakyJoints is a support, education, advocacy, and research organization for people living with arthritis and rheumatic disease.
Read More
Brad Marder, MD: Pegloticase Therapy in Gout Patients Undergoing Dialysis
April 14th 2021This week, Rheumatology Network sat down Brad Marder, MD, co-author of the study, Pegloticase Therapy in Gout Patients Undergoing Dialysis: A USRDS Database Study. Data suggests that pegloticase is successful in the treatment of dialysis patients with uncontrolled gout with potentially lower ESA dose requirements after treatment.
Read More
Daniel J. Lovell, MD, MPH: Juvenile Idiopathic Arthritis
April 5th 2021This week, Rheumatology Network sat down with Daniel J. Lovell, MD, MPH, to discuss his study, “Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.”
Read More
Survey Shows Positive Trends in Digital Health Applications During COVID-19 Pandemic
April 2nd 2021COVID-19 has created new challenges and opportunities in the way that rheumatologists care for chronically ill patients, including the introduction and prevalence of telemedicine and digital health applications (DHAs).
Read More
Fatigue in Patients With Systemic Lupus Erythematosus Linked to Anxiety and Depression
April 1st 2021While some patients with systemic lupus erythematosus (SLE) find it beneficial to receive anti-inflammatory therapy to treat their fatigue, there is increasingly more evidence that chronic diseases increase risk of psychiatric disorders, such as anxiety and depression, which need to be treated differently.
Read More
Tofacitinib Does Not Increase Risk of Venous Thromboembolism in Patients With RA
March 31st 2021Recently, a link between venous thromboembolism (VTE) and Janus Kinase (JAK) inhibitors has emerged, causing the FDA to recommend a black box label for tofacitinib in 2019. New research, however, suggests that tofacitinib had similarly infrequent cases of VTE (<1 per 100) when compared with tumor necrosis factor inhibitors (TNFIs).
Read More
Recruitment Enhancement for Trials Aimed at Individuals At-Risk for Rheumatoid Arthritis
March 30th 2021Investigators identified both facilitators and barriers for trial participation in patients at risk for rheumatoid arthritis (RA) in order to enhance inclusion in trials designed to prevent RA.
Read More
Patients With Rheumatic Disease May Be at Higher Risk of COVID-19 Related Pneumonia
March 25th 2021Patients with inflammatory rheumatic diseases (IRD) may be more likely to acquire severe pneumonia due to COVID-19, especially in patients with autoimmune disease who are being treated with rituximab.
Read More
Investigators Create Systemic Lupus Erythematosus Risk Probability Index (SLERPI) Diagnosis Tool
March 24th 2021Currently, diagnosing a patient with systemic lupus erythematosus (SLE) is a complex process that compares potential lupus with other conditions. It can be challenging and delayed by a period of time, which increases patient uncertainty, referrals, healthcare utilization, increased flares, and organ dysfunction. In this study, machine learning (ML) via artificial intelligence tools based on patient data was used to develop an algorithm to help with SLE diagnosis.
Read More
Anakinra Proves to Be an Effective Alternative Treatment for Gout Flares
March 23rd 2021During the study, which ran from December 2016 through May 2018, 301 flares were treated: 214 with anakinra and 87 with triamcinolone. Both treatment options reduced pain intensity for both first and subsequent flares.
Read More
Guselkumab Sustained Long-Term Efficacy in Patients with Active Psoriatic Arthritis
March 18th 2021Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.
Read More
Rheumatology Research Foundation Announces Additional Funds for Telehealth Studies
March 17th 2021This week, Rheumatology Network sat down to interview S. Louis Bridges, MD, PhD, to highlight the availability of funds for projects exploring telehealth. Bridges is the President of the Rheumatology Research Foundation, as well as Physician-in-Chief and Chair of the Department of Medicine at the Hospital for Special Surgery (HSS), as well as Chief of the Division of Rheumatology at HSS and Weill Cornell College of Medicine.
Read More
Robert Keenan, MD: Efficacy of Combination Therapy for Gout
March 15th 2021Pegloticase in conjunction with immunomodulator combination therapy significantly increased pegloticase responder rates when compared with pegloticase monotherapy for patients with uncontrolled or refractory gout, according to a study. This week, Rheumatology Network interviewed lead investigator, Robert Keenan, MD, to discuss his findings.
Read More
Methotrexate and Pegloticase Combination Therapy Proves to be Effective Gout Treatment
March 12th 2021Pegloticase (pegylated uricase) is medication approved by the US Food and Drug Administration (FDA) designed to lower sUA in patients with uncontrolled gout. However, 26% of patients have infusion-related reactions (IRs), which may be indicative of the development of antidrug antibodies (ADAs). Due to this, physicians often administer immunomodulators in addition to pegloticase in order to prevent ADAs as well as increase the effectiveness of the therapy.
Read More
Patients with Anti-Sjögren’s Syndrome Type A (Anti-SSA) Have Higher Risk of Neurological Involvement
March 11th 2021There were no differences in the occurrence of clinical characteristics between the subset of patients with and without neurological involvement, however disease activity was slightly higher in patients with neurological involvement than those without. Additionally, anti-SSA antibody was significantly higher in patients with neurological involvement and anti-SSB autoantibody was lower.
Read More
Tocilizumab Approved by the FDA for Systemic Sclerosis-Associated Interstitial Lung Disease
March 9th 2021Subcutaneous injection of tocilizumab has been shown to improve the rate of lung function in patients with systemic sclerosis-induced interstitial lung disease when compared with a placebo.
Read More
Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus
March 5th 2021Brian Skaggs, PhD, and Maureen McMahon, MD, sat down with Rheumatology Network to discuss the results of their longitudinal study, “A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus.”
Read More
Patients With Rheumatoid Arthritis Have an Increased Risk of Multimorbidity Burden
March 2nd 2021Investigators believe inflammation, which is known to begin before rheumatoid arthritis (RA) symptoms appear, may be a main factor in the increased prevalence and incidence in multimorbidity for patients with RA.
Read More
Initiation of Febuxostat Does Not Prolong Acute Gout Flares
February 26th 2021“We found that initiation of febuxostat administration during an acute gout flare did not prolong acute flares, and the rate of ‘treat to target’ was higher in the febuxostat group,” investigators concluded. “This may increase patient compliance.”
Read More